·1· · · · UNITED STATES PATENT AND TRADEMARK OFFICE
`
`·2· · · · · · · · · · · · · - - -
`
`·3· · · · ·BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`·4· · · · · · · · · · · · · - - -
`
`·5· · · · · · · ·MYLAN PHARMACEUTICALS INC.,
`· · · · · · · · · · · · · Petitioner,
`·6
`
`·7· · · · · · · · · · · · · · v.
`
`·8
`
`·9· · · · ·POZEN INC. AND HORIZON PHARMA USA, INC.,
`· · · · · · · · · · · · Patent Owners.
`10
`
`11· · · · · · · · · · · · · - - -
`
`12· · · · · · · · · Case No. IPR2017-01995
`· · · · · · · · · · · ·Patent 9,220,698
`13
`
`14· · · · · · · · · · · · · - - -
`
`15
`
`16
`
`17· · · · · ·Videotaped Deposition of DAVID C. METZ,
`
`18· ·M.D., taken at the Hilton Philadelphia City Avenue,
`
`19· ·4200 City Avenue, Philadelphia, Pennsylvania 19131,
`
`20· ·on Friday, May 25, 2018, commencing at 8:58 a.m.,
`
`21· ·before Jennifer Mann, a Shorthand Reporter and
`
`22· ·Notary Public.
`
`23
`
`24
`
`25
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 1 of 76
`
`
`
`·2· · · · · · · · · · · · · - - -
`
`·3· · · · ·BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`·4· · · · · · · · · · · · · - - -
`
`·5· · · · · · · ·MYLAN PHARMACEUTICALS INC.,
`· · · · · · · · · · · · · Petitioner,
`·6
`
`·7· · · · · · · · · · · · · · v.
`
`·8
`
`·9· · · · ·POZEN INC. AND HORIZON PHARMA USA, INC.,
`· · · · · · · · · · · · Patent Owners.
`10
`
`11· · · · · · · · · · · · · - - -
`
`12· · · · · · · · · Case No. IPR2017-01995
`· · · · · · · · · · · ·Patent 9,220,698
`13
`
`14· · · · · · · · · · · · · - - -
`
`15
`
`16
`
`17· · · · · ·Videotaped Deposition of DAVID C. METZ,
`
`18· ·M.D., taken at the Hilton Philadelphia City Avenue,
`
`19· ·4200 City Avenue, Philadelphia, Pennsylvania 19131,
`
`20· ·on Friday, May 25, 2018, commencing at 8:58 a.m.,
`
`21· ·before Jennifer Mann, a Shorthand Reporter and
`
`22· ·Notary Public.
`
`23
`
`24
`
`25
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 1 of 76
`
`
`
`·1· ·APPEARANCES:
`
`·2
`
`·3· · · · · PERKINS COIE LLP
`· · · · · · BY:· ROBERT D. SWANSON, ESQUIRE
`·4· · · · · 700 13th Street, NW
`· · · · · · Suite 600
`·5· · · · · Washington, D.C. 20005
`· · · · · · Attorney for Mylan Pharmaceuticals Inc. and
`·6· · · · · Dr. Metz
`· · · · · · RSwanson@perkinscoie.com
`·7· · · · · (202) 654-1729
`
`·8
`· · · · · · COOLEY LLP
`·9· · · · · BY:· ELLEN A. SCORDINO, ESQUIRE
`· · · · · · 500 Boylston Street
`10· · · · · 14th Floor
`· · · · · · Boston, Massachusetts 02116
`11· · · · · Attorney for Patent Owner Horizon Pharma USA,
`· · · · · · Inc.
`12· · · · · escordino@cooley.com
`· · · · · · (617) 937-2492
`13
`
`14· ·VIA TELEPHONE:
`
`15· · · · · BAKER BOTTS LLP
`· · · · · · BY:· STEPHEN M. HASH, ESQUIRE
`16· · · · · 98 San Jacinto Boulevard
`· · · · · · Suite 1500
`17· · · · · Austin, Texas 78701
`· · · · · · Attorney for Patent Owner Pozen, Inc.
`18· · · · · stephen.hash@bakerbotts.com
`· · · · · · (512) 322-2587
`19
`
`20
`
`21· ·ALSO PRESENT:
`
`22· · · · · Sean Dougherty, Videographer
`
`23
`
`24
`
`25
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 2 of 76
`
`
`
`·1· · · · · · · · · · · · ·I N D E X
`
`·2· ·WITNESS· · · · · · · INTERROGATION BY· · · · · PAGE
`
`·3· ·David C. Metz, M.D.
`
`·4· · · · · · · · · · · ·Ms. Scordino· · · · · · · · 6
`
`·5
`
`·6
`
`·7
`
`·8· · · · · · · · · · ·E X H I B I T S
`
`·9· ·EXHIBIT NUMBER· · · · · DESCRIPTION· · · · · · ·PAGE
`
`10· ·2109· · Confidential - PZ00034117 to PZ00034197· 44
`
`11· ·2110· · Expert Report of David C. Metz, M.D.· · ·68
`
`12· ·2111· · Second Declaration of Dr. Metz· · · · · ·71
`
`13· · · · · · · · · · · ·(Previously marked exhibits,
`
`14· · · · 1001, 1002, 1005, 1006, 1009, and 1010, were
`
`15· · · · referenced and attached.)
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 3 of 76
`
`
`
`·1· · · · · · · · ·LITIGATION SUPPORT INDEX
`
`·2· · · · · · Direction to Witness Not to Answer
`
`·3· ·Page· ·Line· · · · · ·Page· ·Line· · · · · Page Line
`
`·4· · 12· · ·10
`
`·5
`
`·6
`
`·7
`
`·8
`
`·9
`· · · · · · ·Request for Production of Documents
`10
`· · ·Page· ·Line· · · · · ·Page· ·Line· · · · · Page Line
`11
`
`12· · · · · · · · · · · · · (NONE)
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`· · · · · · · · · · · · ·Stipulations
`19
`· · ·Page· ·Line· · · · · ·Page· ·Line· · · · · Page Line
`20
`
`21· · · · · · · · · · · · · (NONE)
`
`22
`
`23
`
`24
`
`25
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 4 of 76
`
`
`
`·1· · · · · · · · · · ·- - -
`
`·2· · · · · · · · · THE VIDEOGRAPHER:· This is a
`
`·3· ·recorded deposition of Dr. David Metz in the
`
`·4· ·matter of Mylan Pharmaceutical versus Pon- --
`
`·5· ·Pozen, Inc. -- my apologies -- being heard
`
`·6· ·before the US Patent Trial and Appeal Board,
`
`·7· ·Case No. IPR2017-01995.· This deposition is
`
`·8· ·being held at 4200 City Ave., Philadelphia, on
`
`·9· ·May 25th, 2018, scheduled to start at 9:00 a.m.
`
`10· · · · · · · · · My name is Sean Dougherty, and I
`
`11· ·am the videographer.· The court reporter is
`
`12· ·Jennifer -- Jennifer Mann -- my apologies.
`
`13· · · · · · · · · Counsel, will you please
`
`14· ·introduce yourselves for the record, at which
`
`15· ·then the court reporter will swear in the
`
`16· ·witness.
`
`17· · · · · · · · · MS. SCORDINO:· Ellen Scordino
`
`18· ·with Cooley LLP, on behalf of Patent Owner
`
`19· ·Horizon.
`
`20· · · · · · · · · MR. HASH:· Steve Hash from Baker
`
`21· ·Botts on behalf of Patent Owner Pozen.
`
`22· · · · · · · · · MR. SWANSON:· Robert Swanson
`
`23· ·from Perkins Coie on behalf of Mylan.
`
`24· · · · · · · · · · ·- - -
`
`25· · · · · · · · · DAVID C. METZ, M.D., after
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 5 of 76
`
`
`
`·1· · · · having been first duly sworn, was examined and
`
`·2· · · · testified as follows:
`
`·3· · · · · · · · · · · · · - - -
`
`·4· · · · · · · · · · · ·THE VIDEOGRAPHER:· The time is
`
`·5· · · · 8:58 a.m.· You may began your questioning.
`
`·6· · · · · · · · · · · · · - - -
`
`·7· · · · · · · · · · DIRECT EXAMINATION
`
`·8· · · · · · · · · · · · · - - -
`
`·9· ·BY MS. SCORDINO:
`
`10· · · · Q.· ·Good morning --
`
`11· · · · A.· ·Starting early.
`
`12· · · · Q.· ·-- Dr. Metz.
`
`13· · · · A.· ·Good morning.
`
`14· · · · Q.· ·Can you please state your full name and
`
`15· ·address for the record?
`
`16· · · · A.· ·David C. Metz, 26 Penarth Road, Bala
`
`17· ·Cynwyd, PA.
`
`18· · · · Q.· ·Now, you've been deposed before, right?
`
`19· · · · A.· ·Correct.
`
`20· · · · Q.· ·How many times?
`
`21· · · · A.· ·Probably about six or seven, I guess.· One
`
`22· ·of which was with yourself.
`
`23· · · · Q.· ·How many times since January of 2017 have
`
`24· ·you been deposed?
`
`25· · · · A.· ·Zero.
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 6 of 76
`
`
`
`·1· · · · Q.· ·And was your last deposition in the
`
`·2· ·Horizon v. Dr. Reddy's, Mylan litigation that you
`
`·3· ·testified at trial?
`
`·4· · · · A.· ·Yes.· I think so.
`
`·5· · · · Q.· ·Okay.· That was -- that was some time ago.
`
`·6· ·I'll just go through the ground rules again, and let
`
`·7· ·me know if you don't -- if you've got any questions.
`
`·8· ·You'll let me know if you don't understand the
`
`·9· ·question.· Otherwise, I will assume that you've
`
`10· ·understood when you answer.
`
`11· · · · A.· ·Sure.
`
`12· · · · Q.· ·You'll answer with verbal responses?
`
`13· · · · A.· ·Sure.
`
`14· · · · Q.· ·And we'll try not to talk over each other,
`
`15· ·so the court reporter can get down what we're both
`
`16· ·saying.· Okay?
`
`17· · · · A.· ·Okay.
`
`18· · · · Q.· ·Your attorney may object, but unless he
`
`19· ·instructs you not to answer, you'll still answer the
`
`20· ·question.
`
`21· · · · A.· ·That's fine.
`
`22· · · · Q.· ·We'll take breaks about every hour, but if
`
`23· ·you would like a break before then or if you need to
`
`24· ·take a call, just let me know and we'll take a
`
`25· ·break.· I just ask that if there's a pending
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 7 of 76
`
`
`
`·1· ·question, you try to answer the question before we
`
`·2· ·go on break.
`
`·3· · · · A.· ·Sure.
`
`·4· · · · Q.· ·Is there any reason why you cannot testify
`
`·5· ·truthfully today?
`
`·6· · · · A.· ·No.
`
`·7· · · · Q.· ·How did you prepare for this deposition?
`
`·8· · · · A.· ·I spent yesterday afternoon with
`
`·9· ·Mr. Swanson in this very room going over my report
`
`10· ·and the references attached thereto.
`
`11· · · · Q.· ·When you say "the references attached
`
`12· ·thereto," do you mean the exhibits that you cited in
`
`13· ·the report?
`
`14· · · · A.· ·That is correct.
`
`15· · · · Q.· ·Outside of the meeting with Dr. --
`
`16· ·Mr. Swanson yesterday, did you do anything else to
`
`17· ·prepare for today's deposition?
`
`18· · · · A.· ·I reread my report last night before I
`
`19· ·went to sleep.
`
`20· · · · Q.· ·Prior to yesterday, did you do anything to
`
`21· ·prepare for your deposition?
`
`22· · · · A.· ·Well, we set up a time and we arranged to
`
`23· ·have this meeting.· This is part of a much bigger
`
`24· ·effort, but I didn't -- I'm not counting all that
`
`25· ·stuff as part of this particular deposition today,
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 8 of 76
`
`
`
`·1· ·so no.
`
`·2· · · · Q.· ·And when you say "part of a much bigger
`
`·3· ·effort," are you referring to the district court
`
`·4· ·litigation relating to the '698 patent?
`
`·5· · · · A.· ·Correct.
`
`·6· · · · Q.· ·So, now just talking about for this IPR,
`
`·7· ·did you meet with any attorneys from Dr. Reddy's?
`
`·8· · · · A.· ·Well, some people from Dr. Reddy's had
`
`·9· ·contacted me in the hopes of joining this
`
`10· ·litigation.· And so, I did speak with them about it,
`
`11· ·but I was told afterwards that behind the scenes
`
`12· ·there had been some discussions and Dr. Reddy's was
`
`13· ·not going to be involved today.
`
`14· · · · Q.· ·Okay.· And when were you contacted by
`
`15· ·Dr. Reddy's?
`
`16· · · · A.· ·That was the last week in March, first
`
`17· ·week in April, I think, because I was out of the
`
`18· ·country, so I know it was during that period, but I
`
`19· ·can't remember exactly which day.
`
`20· · · · Q.· ·And during that contact, they were
`
`21· ·specifically talking to you about an IPR related to
`
`22· ·the '698?
`
`23· · · · A.· ·Correct --
`
`24· · · · · · · · · · · ·MR. SWANSON:· Dr. Metz, just
`
`25· · · · to -- be careful not to, you know, divulge any
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 9 of 76
`
`
`
`·1· · · · of the substantive conversations that you had,
`
`·2· · · · but you can answer the basic outline of the
`
`·3· · · · question.
`
`·4· · · · · · · · · · · ·THE WITNESS:· Can you repeat
`
`·5· · · · that question, please?
`
`·6· · · · · · · · · · · ·MS. SCORDINO:· Can you read back
`
`·7· · · · the question?
`
`·8· · · · · · · · · · · · · - - -
`
`·9· · · · · · · · · · · ·(Whereupon, the court reporter
`
`10· · · · read back the record as requested.)
`
`11· · · · · · · · · · · · · - - -
`
`12· ·BY MS. SCORDINO:
`
`13· · · · Q.· ·So, I'll -- so, I'll ask it --
`
`14· · · · A.· ·I think that's correct, yes.
`
`15· · · · Q.· ·And were you engaged with them to
`
`16· ·participate in the IPR related to the '698 patent?
`
`17· · · · A.· ·I'm not sure how to exactly answer that
`
`18· ·question.· I spoke to them and said yes, I would be
`
`19· ·potentially interested in -- in doing that.· We even
`
`20· ·started working a little bit on a report, but then I
`
`21· ·was told afterwards that this was not going to
`
`22· ·happen, so I wasn't engaged as such.· I'm already
`
`23· ·engaged with Dr. Reddy's representatives for the
`
`24· ·district court litigation, so I wouldn't have had to
`
`25· ·be formally engaged for this, I assume.
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 10 of 76
`
`
`
`·1· · · · Q.· ·So, with respect to the IPR and the
`
`·2· ·petition, you drafted a declaration or you began
`
`·3· ·drafting a declaration for Dr. Reddy's?
`
`·4· · · · A.· ·I didn't actually produce a document as
`
`·5· ·such, but we started talking about how it would
`
`·6· ·compare with the document that you have for today's
`
`·7· ·discussion.
`
`·8· · · · Q.· ·Okay.· And what did you talk about?
`
`·9· · · · · · · · · · · ·MR. SWANSON:· Dr. Metz, I would
`
`10· · · · caution you not to answer, you know, any
`
`11· · · · specifics.· You can talk about the fact that
`
`12· · · · you spoke with Dr. Reddy's, but, you know, do
`
`13· · · · not answer any questions about the substance of
`
`14· · · · those conversations.
`
`15· ·BY MS. SCORDINO:
`
`16· · · · Q.· ·So, can you answer that question without
`
`17· ·your counsel's instruction to not answer?
`
`18· · · · A.· ·I don't understand.
`
`19· · · · Q.· ·Do you remember the content of that
`
`20· ·conversation?
`
`21· · · · A.· ·The content of that discussion was --
`
`22· · · · · · · · · · · ·MR. SWANSON:· Well, hold on,
`
`23· · · · Dr. Metz.
`
`24· ·BY MS. SCORDINO:
`
`25· · · · Q.· ·So, I'm just asking if you remember the
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 11 of 76
`
`
`
`·1· ·content.· He's instructed you not tell me the
`
`·2· ·content.· I just want to know if you remember the
`
`·3· ·content.
`
`·4· · · · A.· ·I -- I remember being contacted. I
`
`·5· ·remember saying fine, I will do it.· I remember
`
`·6· ·discussing that we would have a similar type report,
`
`·7· ·but it never went any further than -- than that.
`
`·8· · · · Q.· ·Okay.· When you -- what -- what do you
`
`·9· ·mean by "similar type report"?
`
`10· · · · · · · · · · · ·MR. SWANSON:· Dr. Metz, I will
`
`11· · · · instruct you not to answer that question.
`
`12· · · · Counsel --
`
`13· · · · · · · · · · · ·MS. SCORDINO:· Okay.· So, Rob is
`
`14· · · · it your position that he has been engaged by
`
`15· · · · DRL for an IPR petition related to the '698
`
`16· · · · patent?
`
`17· · · · · · · · · · · ·MR. SWANSON:· No.
`
`18· · · · · · · · · · · ·THE WITNESS:· And it's not mine
`
`19· · · · either.
`
`20· ·BY MS. SCORDINO:
`
`21· · · · Q.· ·Okay.· Then those conversations are not
`
`22· ·privileged.· They are not your attorney for purposes
`
`23· ·of an IPR if you've not been engaged by them, and
`
`24· ·so, you can answer the question.· It's an improper
`
`25· ·instruction to not answer.
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 12 of 76
`
`
`
`·1· · · · · · · · · · · ·Are you going to -- so, are you
`
`·2· ·going to listen to your counsel's instruction, or
`
`·3· ·are you going to answer the question?
`
`·4· · · · · · · · · · · ·MR. SWANSON:· Dr. Metz, you can,
`
`·5· · · · you know, give -- give some sort of basic
`
`·6· · · · answer as to the question, but, you know,
`
`·7· · · · please move on from this.
`
`·8· · · · · · · · · · · ·THE WITNESS:· Okay.
`
`·9· ·BY MS. SCORDINO:
`
`10· · · · Q.· ·So -- so as you're not confused, the
`
`11· ·question is, can you tell me what you meant by, they
`
`12· ·said that you would have a similar report to the one
`
`13· ·that you had already done for the IPR with Mylan.
`
`14· · · · A.· ·That the report that would come out of
`
`15· ·that engagement with -- with the -- the IPR would be
`
`16· ·joining this current litigation.· So, I would have
`
`17· ·assumed that it would have been a Pozen versus Mylan
`
`18· ·and Dr. Reddy versus Pozen just versus Mylan.· But I
`
`19· ·understand that today I am here representing Mylan
`
`20· ·and only Mylan.
`
`21· · · · Q.· ·Okay.· So, with respect to DRL, what did
`
`22· ·the DRL attorneys tell you about the IPR?
`
`23· · · · A.· ·He told me that he was interested in his
`
`24· ·company joining the current litigation and I would
`
`25· ·-- would I be willing to -- to provide a declaration
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 13 of 76
`
`
`
`·1· ·for that as well, along similar lines.· And we then
`
`·2· ·went back to my original -- he asked me if I had a
`
`·3· ·contract that was exclusive to Mylan or not, and I
`
`·4· ·said I didn't think so.
`
`·5· · · · · · · · · · · ·And then he sent me the copy of
`
`·6· ·my contract and we both looked at it.· I was in
`
`·7· ·another continent, so this was all -- it wasn't done
`
`·8· ·by face-to-face or by phone.· It was actually done
`
`·9· ·by e-mail.· And I looked at his declaration that
`
`10· ·he -- he sent me, which was the same -- the -- the
`
`11· ·contract that he sent me, which is the same contract
`
`12· ·that I had.· And I said, sure, that seems to me that
`
`13· ·it's okay.· I'm happy to do it.· And then I was
`
`14· ·contacted afterwards and was told that it isn't
`
`15· ·happening.· What went on amongst the various
`
`16· ·lawyers, I -- I have no idea.
`
`17· · · · Q.· ·So, you did not review your declaration
`
`18· ·that you provided to Mylan with DRL's counsel and
`
`19· ·start to make edits to it?
`
`20· · · · · · · · · · · ·MR. SWANSON:· Objec- -- hold on.
`
`21· · · · Objection.· Asked and answered.
`
`22· · · · · · · · · · · ·THE WITNESS:· I definitively did
`
`23· · · · not do that.· I was told I was actually not
`
`24· · · · allowed to share what I had done with Mylan
`
`25· · · · until they had sorted out what they were going
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 14 of 76
`
`
`
`·1· · · · to do.
`
`·2· ·BY MS. SCORDINO:
`
`·3· · · · Q.· ·Okay.
`
`·4· · · · A.· ·There was a lot of legalese behind the
`
`·5· ·scenes that I think is beyond my understanding of
`
`·6· ·this case.
`
`·7· · · · Q.· ·Did you have any substantive discussions
`
`·8· ·with DRL with respect to the '698 petition and a
`
`·9· ·declaration by yourself?
`
`10· · · · · · · · · · · ·MR. SWANSON:· Objection.· Asked
`
`11· · · · and answered.· Counsel, please move on.
`
`12· · · · · · · · · · · ·THE WITNESS:· No.
`
`13· ·BY MS. SCORDINO:
`
`14· · · · Q.· ·Did you speak with any employees of Mylan
`
`15· ·regarding your IPR declaration?
`
`16· · · · A.· ·No.
`
`17· · · · Q.· ·Did you speak with any authors of the
`
`18· ·prior art regarding your declaration?
`
`19· · · · A.· ·No.· I know many of them, but I have not
`
`20· ·spoken with any of them about this.
`
`21· · · · Q.· ·Did you speak with Dr. Mayersohn about
`
`22· ·your declaration?
`
`23· · · · A.· ·No.
`
`24· · · · Q.· ·Did you speak with Dr. Mayersohn about his
`
`25· ·declaration?
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 15 of 76
`
`
`
`·1· · · · A.· ·No.
`
`·2· · · · Q.· ·Did you review the deposition transcript
`
`·3· ·of Dr. Mayersohn that was taken earlier this week?
`
`·4· · · · A.· ·No.
`
`·5· · · · Q.· ·Did you discuss the substance of
`
`·6· ·Dr. Mayersohn's deposition in preparation for your
`
`·7· ·deposition today?
`
`·8· · · · · · · · · · · ·MR. SWANSON:· I object.· And,
`
`·9· · · · Dr. Metz, you can give this a yes-or-no answer,
`
`10· · · · but do not discuss any substance of discussions
`
`11· · · · that were had, if any.
`
`12· · · · · · · · · · · ·THE WITNESS:· Yes.
`
`13· ·BY MS. SCORDINO:
`
`14· · · · Q.· ·Did anything in that discussion about
`
`15· ·Dr. Mayersohn's deposition change any of the
`
`16· ·opinions you intend to give today?
`
`17· · · · A.· ·No.
`
`18· · · · Q.· ·Did anything in that discussion about
`
`19· ·Dr. Mayersohn's deposition change any of the
`
`20· ·testimony that you're going to give today?
`
`21· · · · A.· ·No.
`
`22· · · · Q.· ·Are there any statements in your
`
`23· ·declaration -- declaration that you believe are
`
`24· ·wrong or incorrect?
`
`25· · · · A.· ·No.
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 16 of 76
`
`
`
`·1· · · · Q.· ·How did you come to be an expert retained
`
`·2· ·by just Mylan for this IPR?
`
`·3· · · · A.· ·I -- as you know from prior -- my prior
`
`·4· ·testimony with you, I was contacted by a company I
`
`·5· ·do consulting work for, GLG, as to whether I would
`
`·6· ·be interested in doing a patent law case. I
`
`·7· ·answered yes.· They contacted Perkins Coie, namely
`
`·8· ·Melody Glazer, who had originally made the inquiry,
`
`·9· ·put the two of us in contact with one another.· And
`
`10· ·I was originally actually employed by as a -- by GLG
`
`11· ·in providing service to Mylan.
`
`12· · · · · · · · · · · ·Mylan subsequently expanded that
`
`13· ·to include in addition Dr. Reddy's and Lupin. I
`
`14· ·think there was another company involved, but I
`
`15· ·wasn't involved with them.· It was those three.
`
`16· ·That's the way it's structured at the moment, is if
`
`17· ·I do work for only one of the parties, then I'm only
`
`18· ·billing that party.· If I do work that is in
`
`19· ·combination, then I bill all of the parties.· This
`
`20· ·particular issue is only relating to Mylan, and I
`
`21· ·was told such when we drew it up.
`
`22· · · · Q.· ·So -- so, when did you draw it up, and by
`
`23· ·"it," are you referring to a contract related to
`
`24· ·this IPR?
`
`25· · · · A.· ·I'm -- I'm talking to the -- I'm talking
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 17 of 76
`
`
`
`·1· ·about the declaration.
`
`·2· · · · Q.· ·Okay.
`
`·3· · · · A.· ·That -- my report that's to be discussed
`
`·4· ·today.· And that was -- I'm going to time it again
`
`·5· ·to my trip.· So, it was towards the middle, end of
`
`·6· ·March.
`
`·7· · · · Q.· ·So, towards the middle, end of March, you
`
`·8· ·were contacted by Mylan attorneys and asked to
`
`·9· ·provide a declaration for this IPR?
`
`10· · · · A.· ·That is correct.
`
`11· · · · · · · · · · · ·Now, maybe it was late February,
`
`12· ·early -- I can't be precise, but it was somewhere
`
`13· ·around the spring.
`
`14· · · · Q.· ·And prior to that contact, had you
`
`15· ·reviewed the '698 patent?
`
`16· · · · A.· ·I honestly don't remember.
`
`17· · · · Q.· ·You are currently an expert on behalf of
`
`18· ·Mylan, DRL, and Lupin in the district court case
`
`19· ·involving the '698 patent, correct?
`
`20· · · · A.· ·I believe so.
`
`21· · · · Q.· ·And do you have a separate engagement
`
`22· ·governing that litigation?
`
`23· · · · A.· ·No.
`
`24· · · · Q.· ·Now, you recently submitted an expert
`
`25· ·report in that litigation, correct?
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 18 of 76
`
`
`
`·1· · · · A.· ·I don't know what you mean by "recent,"
`
`·2· ·but I have submitted, yes.
`
`·3· · · · Q.· ·And for that expert report, did you work
`
`·4· ·with attorneys from each of the defendants?
`
`·5· · · · · · · · · · · ·MR. SWANSON:· Objection.· What
`
`·6· · · · is the relevance of this questioning to the
`
`·7· · · · IPR?
`
`·8· ·BY MS. SCORDINO:
`
`·9· · · · Q.· ·You can still answer.
`
`10· · · · A.· ·I still can answer?
`
`11· · · · · · · · · · · ·MR. SWANSON:· You can answer.
`
`12· · · · · · · · · · · ·MS. SCORDINO:· Um-hmm.
`
`13· · · · · · · · · · · ·THE WITNESS:· Can you tell me
`
`14· · · · that again?· I'm sorry.
`
`15· · · · · · · · · · · ·MR. SWANSON:· Can you repeat the
`
`16· · · · question?
`
`17· · · · · · · · · · · · · - - -
`
`18· · · · · · · · · · · ·(Whereupon, the court reporter
`
`19· · · · read back the record as requested.)
`
`20· · · · · · · · · · · · · - - -
`
`21· · · · · · · · · · · ·THE WITNESS:· Yes.· Usually --
`
`22· · · · or not usually.· Always with multiple parties
`
`23· · · · represented on a -- on the same meeting by
`
`24· · · · phone usually.· So, I may have been meeting
`
`25· · · · with one person, but there were people from the
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 19 of 76
`
`
`
`·1· · · · other companies participating.· I -- the only
`
`·2· · · · time I actually had individual contact with one
`
`·3· · · · company only was the discussion about if
`
`·4· · · · Dr. Reddy's was going to join this, as we've
`
`·5· · · · already discussed, and at times with just the
`
`·6· · · · Mylan representatives for this particular
`
`·7· · · · declaration.
`
`·8· · · · · · · · · · · ·MS. SCORDINO:· And, Counsel, on
`
`·9· · · · the record, I'd like to clarify that objections
`
`10· · · · in IPRs are limited to objection to form.· If
`
`11· · · · you believe it's outside the scope, the proper
`
`12· · · · procedure is to make a motion to strike.· Its
`
`13· · · · is -- it is not to insert speaking objections.
`
`14· · · · · · · · · · · ·MR. SWANSON:· And for the
`
`15· · · · record, a relevance objection is not a form
`
`16· · · · objection.
`
`17· · · · · · · · · · · ·You can proceed.
`
`18· · · · · · · · · · · ·MS. SCORDINO:· Again, the way to
`
`19· · · · handle that is with the motion to strike the
`
`20· · · · testimony.
`
`21· ·BY MS. SCORDINO:
`
`22· · · · Q.· ·What is your current occupation, Dr. Metz?
`
`23· · · · A.· ·I'm a gastroenterologist.
`
`24· · · · Q.· ·And do you still treat patients?
`
`25· · · · A.· ·Yes.
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 20 of 76
`
`
`
`·1· · · · Q.· ·And are you still involved in research?
`
`·2· · · · A.· ·Yes.
`
`·3· · · · Q.· ·What types of research are you involved in
`
`·4· ·currently?
`
`·5· · · · A.· ·My major area of activity at the moment is
`
`·6· ·neuroendocrine tumors and upper GI disease states,
`
`·7· ·with a specific interest in proton pump inhibitors
`
`·8· ·and other antisecretory drugs.· But I have
`
`·9· ·researched protocols in a variety of -- of areas in
`
`10· ·gastroenterology and neuroendocrinology.
`
`11· · · · Q.· ·And what -- how many patients do you
`
`12· ·treat, approximately?
`
`13· · · · A.· ·I have a very big practice.· I do four
`
`14· ·days of clinical work a week, two of which are
`
`15· ·endoscopic, two of which are seeing patients.· I run
`
`16· ·a tumor board once a month that has about 25, 30
`
`17· ·patients on it each time.· My daily patient ex- --
`
`18· ·exposure is probably 15 or 20 patients per day.· And
`
`19· ·I've been doing this for 30 years, so you can
`
`20· ·multiply that up, it's probably thousands and
`
`21· ·thousands.
`
`22· · · · Q.· ·Do you currently write prescriptions?
`
`23· · · · A.· ·Yes.
`
`24· · · · Q.· ·And do you write prescriptions for PPIs?
`
`25· · · · A.· ·All the time.
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 21 of 76
`
`
`
`·1· · · · Q.· ·And have you ever written a prescription
`
`·2· ·for Vimovo?
`
`·3· · · · A.· ·No.
`
`·4· · · · Q.· ·Do you treat your patients with NSAIDs?
`
`·5· · · · A.· ·I have many, many patients that are on
`
`·6· ·NSAIDs.· I generally do not prescribe NSAIDs.
`
`·7· ·Although, on occasions, rare occasions for specific
`
`·8· ·indications, I will consider NSAIDs and have
`
`·9· ·prescribed NSAIDs.· I do not tend to prescribe
`
`10· ·chronic NSAIDs for arthritic conditions.
`
`11· · · · Q.· ·Do you know what an IPR is?
`
`12· · · · A.· ·I think I do.
`
`13· · · · Q.· ·What's your understanding?
`
`14· · · · A.· ·My understanding is that this is a review
`
`15· ·that is performed by the patent office between a
`
`16· ·party that has a patent and a party that is
`
`17· ·contesting that patent to determine if it is truly a
`
`18· ·valid patent.
`
`19· · · · Q.· ·And do you understand that here, US Patent
`
`20· ·No. 9220698 is being challenged by IPR?
`
`21· · · · A.· ·That is correct.
`
`22· · · · Q.· ·And will you understand -- I think we have
`
`23· ·been -- but if I continue to refer to this as the
`
`24· ·'698 patent?
`
`25· · · · A.· ·Correct.
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 22 of 76
`
`
`
`·1· · · · Q.· ·In connection with preparing your
`
`·2· ·declaration, did you review the '698 patent?
`
`·3· · · · A.· ·Yes.
`
`·4· · · · Q.· ·When was the last time you reviewed the
`
`·5· ·claims of that patent?
`
`·6· · · · A.· ·Yesterday.
`
`·7· · · · Q.· ·And did you review all seven claims of the
`
`·8· ·patent?
`
`·9· · · · A.· ·I believe so.
`
`10· · · · Q.· ·And did you review all seven claims of the
`
`11· ·patent in connection with preparing your
`
`12· ·declaration?
`
`13· · · · A.· ·Sure.
`
`14· · · · Q.· ·Have you reviewed Mylan's petition for
`
`15· ·IPR?
`
`16· · · · A.· ·Can I see my declaration, so I can see if
`
`17· ·that's attached?
`
`18· · · · Q.· ·Sure.· Sure.· I'll represent to you that
`
`19· ·it's -- that it's not attached.· It's the petition
`
`20· ·that your declaration supports that was filed with
`
`21· ·the PTAB.
`
`22· · · · A.· ·That it's not in Appendix B?
`
`23· · · · Q.· ·No.
`
`24· · · · A.· ·Then I did not.
`
`25· · · · Q.· ·Okay.· But I will give you your
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 23 of 76
`
`
`
`·1· ·declaration, so I'm handing you what's already been
`
`·2· ·marked as Exhibit 1002.
`
`·3· · · · A.· ·It looks -- oh, it's got my CV.· I was
`
`·4· ·trying to work out why it's so thick.· Okay.
`
`·5· · · · Q.· ·Did you review the Patent Office
`
`·6· ·institution of the IPR for the '698?
`
`·7· · · · A.· ·The Patent Office institution, is that a
`
`·8· ·document or a building or...
`
`·9· · · · Q.· ·It's a decision.· It's a -- it's a
`
`10· ·document.· So, the Patent Office instituted the IPR
`
`11· ·in this case, and so, they provided a decision as to
`
`12· ·why they --
`
`13· · · · A.· ·As to whether this can go forward, no.
`
`14· · · · Q.· ·So, I -- I believe you said that you were
`
`15· ·contacted by Mylan about this IPR at the middle or
`
`16· ·end of March.· When did you begin working on the
`
`17· ·declaration for the IPR?
`
`18· · · · A.· ·Immediately, because I was -- I knew I was
`
`19· ·going away, and we have a -- a brief period, a few
`
`20· ·weeks really to get that together before I left.
`
`21· · · · Q.· ·Are you aware that the district court
`
`22· ·issued an opinion in the first round of litigation,
`
`23· ·the litigation where you testified at trial?
`
`24· · · · A.· ·I -- I do.· I am.
`
`25· · · · Q.· ·And did you review that opinion?
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 24 of 76
`
`
`
`·1· · · · A.· ·No.
`
`·2· · · · Q.· ·And what's your understanding of that
`
`·3· ·opinion?
`
`·4· · · · A.· ·That it is being appealed by our side.
`
`·5· · · · Q.· ·Do you know specifically what's being
`
`·6· ·appealed?
`
`·7· · · · A.· ·No.
`
`·8· · · · Q.· ·Are you aware that the opinion involves
`
`·9· ·patents that are listed in the Orange Book
`
`10· ·concerning Vimovo?
`
`11· · · · A.· ·I don't know what the Orange Book is.
`
`12· · · · Q.· ·So, you're not familiar with the FDA's
`
`13· ·Orange Book?
`
`14· · · · A.· ·I -- I know who the FDA are, but I'm not
`
`15· ·sure what you're referring to when you say the
`
`16· ·Orange Book.
`
`17· · · · Q.· ·Okay.· Would you agree with me that the
`
`18· ·two patents in the earlier litigation are related to
`
`19· ·Vimovo?
`
`20· · · · · · · · · · · ·MR. SWANSON:· Object to form.
`
`21· · · · · · · · · · · ·THE WITNESS:· I don't think
`
`22· · · · either of the two patents you're referring to
`
`23· · · · use the word "Vimovo" anywhere, but I think
`
`24· · · · they refer to the materials that are used to
`
`25· · · · make up Vimovo.· So, from one step removed, I'd
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 25 of 76
`
`
`
`·1· · · · say yes.
`
`·2· ·BY MS. SCORDINO:
`
`·3· · · · Q.· ·And would you agree with me that the '698
`
`·4· ·patent that we're here to talk about today is also
`
`·5· ·related to Vimovo?
`
`·6· · · · · · · · · · · ·MR. SWANSON:· Object to form.
`
`·7· · · · · · · · · · · ·THE WITNESS:· I would agree.
`
`·8· ·BY MS. SCORDINO:
`
`·9· · · · Q.· ·And are you being compensated at $700 an
`
`10· ·hour for your work in this matter?
`
`11· · · · A.· ·That is correct.
`
`12· · · · Q.· ·And as -- about how many hours have you
`
`13· ·billed to the IPR declaration and preparing for this
`
`14· ·deposition?
`
`15· · · · A.· ·How many I've billed would be so far, I
`
`16· ·would say, two or three hours.
`
`17· · · · Q.· ·And is that about the amount of time you
`
`18· ·spent working on your declaration for this IPR?
`
`19· · · · A.· ·Well, it would be almost entirely working
`
`20· ·on the declaration.· But I haven't billed all my
`
`21· ·time yet.
`
`22· · · · Q.· ·So, approximately, how much time have you
`
`23· ·spent working on this matter?
`
`24· · · · A.· ·Well, I've billed up through the end of
`
`25· ·March, I believe.· I have an outstanding bill for
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 26 of 76
`
`
`
`·1· ·some monies in April, although I can't say how much
`
`·2· ·of that was for this and how much of that was for
`
`·3· ·everything else without guessing.· And then I
`
`·4· ·haven't billed anything for May, which would really
`
`·5· ·primarily include yesterday's preparation, so that
`
`·6· ·hasn't really been included yet, which was about
`
`·7· ·five hours, I think.
`
`·8· · · · Q.· ·Did you talk to anyone on the phone
`
`·9· ·yesterday during your preparation with Mr. Swanson?
`
`10· · · · A.· ·Yes.· My sister called me in the midst of
`
`11· ·it.
`
`12· · · · Q.· ·Did you talk to anyone on the phone about
`
`13· ·the substance of your declaration or the substance
`
`14· ·of your testimony today?
`
`15· · · · A.· ·No.
`
`16· · · · Q.· ·Can you describe for me the process by
`
`17· ·which your declaration was created?
`
`18· · · · A.· ·Well, it was a collaboration really, since
`
`19· ·I'm unaware of all the legalese and -- as I keep on
`
`20· ·getting reminded during these -- these discussions.
`
`21· ·And I find that doing this kind of work for patent
`
`22· ·law specifically very, very confusing.
`
`23· · · · · · · · · · · ·So, I have my medical knowledge
`
`24· ·and proposals, and the lawyers have the legalese
`
`25· ·side of it, and essentially a document arises from
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 27 of 76
`
`
`
`·1· ·back and forth discussions and e-mails and phone
`
`·2· ·calls, et cetera.· So, it was a true collaboration.
`
`·3· ·I would say that the original -- the order of who I
`
`·4· ·am and what I do and what the legal requirements are
`
`·5· ·and what I've been told is sort of all stated up
`
`·6· ·front by the lawyers.· And my involvement is
`
`·7· ·primarily to accept that and understand that and
`
`·8· ·provide medical, clinical input as necessary to
`
`·9· ·support my comments to which I assign.
`
`10· · · · Q.· ·Which attorneys did you work with?
`
`11· · · · A.· ·With Autumn Nero, Melody Glazer, and Rob
`
`12· ·Swanson.
`
`13· · · · Q.· ·Any other attorneys?
`
`14· · · · A.· ·Not that -- for this IPR, no one else
`
`15· ·jumps to my mind.· I don't think there are any
`
`16· ·others.· There may have been, but I'm not -- I'm not
`
`17· ·sure.· I don't think so.
`
`18· · · · Q.· ·Can we turn to Attachment B in your
`
`19· ·declaration?
`
`20· · · · A.· ·Got it.
`
`21· · · · Q.· ·These are the materials you reviewed for
`
`22· ·your declaration, correct?
`
`23· · · · A.· ·That is correct.
`
`24· · · · Q.· ·And these are the materials you rely on
`
`25· ·for your opinions, correct?
`
`Patent Owners' Ex. 2027
`IPR2018-00272
`Page 28 of 76
`
`
`
`·1· · · · A.· ·Correct.
`
`·2· · · · Q.· ·How did you select these materials?
`
`·3· · · · A.· ·Well, I know of the -- well, let's start
`
`·4· ·with the beginning.· The patents weren't selected by
`
`·5· ·me.· They're obviously in discussion and a part of
`
`·6· ·the whole deal and were provided to me by the
`
`·7· ·lawyers.
`
`·8· · · · · · · · · · · ·So, if we run down from the top
`
`·9· ·down, the Colin Howden article -- I know Colin well.
`
`10· ·I've worked with him for many years, and I have used
`
`11· ·that a
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
